Overview

A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia

Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study consists of a 4 week run-in period with a Ca based phosphate binder and 12 weeks treatment period by MCI-196 or placebo, (both on Ca based phosphate binder). During the treatment period, MCI-196 or placebo will be titrated every 3 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation